Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α  C. Scagnolari, S. Trombetti, A. Soldà, M. Milella, G.B. Gaeta, G. Angarano, G. Scotto, N. Caporaso, F. Morisco, R. Cozzolongo, G. Giannelli, M. Fasano, T. Santantonio, G. Antonelli  Clinical Microbiology and Infection  Volume 18, Issue 10, Pages 1033-1039 (October 2012) DOI: 10.1111/j.1469-0691.2011.03729.x Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1. Development of anti-interferon (IFN) neutralizing antibody in patients with chronic hepatitis C (CHC). Analysis was performed before (T0) and after 6 months (T6) of pegylayed (PEG) -IFN-α plus ribavirin treatment in patients with CHC who had (white bars) or had not (black bars) been treated previously with a conventional IFN-based regimen. p <0.05 using the chi-square test. Clinical Microbiology and Infection 2012 18, 1033-1039DOI: (10.1111/j.1469-0691.2011.03729.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2. Specificities of anti-interferon (IFN) neutralizing antibody during leucocyte (LE) -IFN-α therapy. Serum samples were collected from patient 2 before (T0) and after 1 (T1), 2 (T2), 3 (T3), 4 (T4), 5 (T5), and 6 (T6) months of therapy with LE-IFN-α. Serum neutralizing activity against different IFN-α preparations (LE-IFN-α; Multiferon® and subtypes of IFN-α) was expressed in tenfold reduction units (TRU)/mL. Clinical Microbiology and Infection 2012 18, 1033-1039DOI: (10.1111/j.1469-0691.2011.03729.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions